U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H31FN4O8
Molecular Weight 558.5554
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERAVACYCLINE

SMILES

[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]5(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]5([H])C2

InChI

InChIKey=HLFSMUUOKPBTSM-ISIOAQNYSA-N
InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1

HIDE SMILES / InChI
Molecular Formula C27H31FN4O8
Molecular Weight 558.5554
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens. It was first approved by the FDA on August 27, 2018. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.

Originator

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
30S ribosomal protein S4
2
Target ID: P0A7V8
Gene ID: 947793.0
Gene Symbol: rpsD
Target Organism: Escherichia coli (strain K12)
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
XERAVA

Approved Use

XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. (1.1) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). (1.1) To reduce the development of drug -resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2)

Launch Date

2018
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2125 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1825 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg 2 times / day steady-state, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4305 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6309 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg 2 times / day steady-state, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg 2 times / day steady-state, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
15.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg 2 times / day steady-state, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ERAVACYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg/kg 1 times / day single, intravenous
Highest studied dose
Dose: 3 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 3 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (grade 1-2, >10)
Vomiting (grade 1-2, <10%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
1.5 mg/kg 1 times / day single, intravenous
MTD
Dose: 1.5 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1.5 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
1 mg/kg 1 times / day single, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Disc. AE: Pyrexia...
AEs leading to
discontinuation/dose reduction:
Pyrexia (2.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
0.25 mg/kg 1 times / day single, intravenous
Dose: 0.25 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Disc. AE: Pyrexia...
AEs leading to
discontinuation/dose reduction:
Pyrexia (2.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
1.5 mg/kg 1 times / day single, intravenous (min)
Dose: 1.5 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1.5 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
DLT: Nausea, Vomiting...
Dose limiting toxicities:
Nausea
Vomiting
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
1 mg/kg 2 times / day multiple, intravenous
MTD|Highest studied dose
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Disc. AE: Phlebitis superficial...
AEs leading to
discontinuation/dose reduction:
Phlebitis superficial (4.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
1 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Disc. AE: Decreased appetite, Nausea...
AEs leading to
discontinuation/dose reduction:
Decreased appetite (4.2%)
Nausea (4.2%)
Vomiting (4.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
AEs

AEs

AESignificanceDosePopulation
Vomiting grade 1-2, <10%
3 mg/kg 1 times / day single, intravenous
Highest studied dose
Dose: 3 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 3 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Nausea grade 1-2, >10
3 mg/kg 1 times / day single, intravenous
Highest studied dose
Dose: 3 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 3 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Pyrexia 2.4%
Disc. AE
1 mg/kg 1 times / day single, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Pyrexia 2.4%
Disc. AE
0.25 mg/kg 1 times / day single, intravenous
Dose: 0.25 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Nausea DLT
1.5 mg/kg 1 times / day single, intravenous (min)
Dose: 1.5 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1.5 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
Vomiting DLT
1.5 mg/kg 1 times / day single, intravenous (min)
Dose: 1.5 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 1.5 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
healthy, 18–48 years
n = 42
Health Status: healthy
Age Group: 18–48 years
Sex: M+F
Population Size: 42
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
Phlebitis superficial 4.2%
Disc. AE
1 mg/kg 2 times / day multiple, intravenous
MTD|Highest studied dose
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Decreased appetite 4.2%
Disc. AE
1 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Nausea 4.2%
Disc. AE
1 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Vomiting 4.2%
Disc. AE
1 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 1 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
healthy, 19–50 years
n = 24
Health Status: healthy
Age Group: 19–50 years
Sex: M+F
Population Size: 24
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf
https://pubmed.ncbi.nlm.nih.gov/30150464/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
781
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C8
911

CYP2C19
1478

CYP3A4/5
278

P-gp
1461

BCRP
699

BSEP
402

OATP1B1
788

OATP1B3
706

OAT1
599

OAT3
642

OCT1
512

OCT2
647

MATE1
306

MATE2
263
CYP3A4/5
85

UGT
192

CYP3A
191

P-gp
1537

BCRP
561

BSEP
52

OATP1B1
406

OATP1B3
350

OAT1
326

OAT3
339

OCT1
327

OCT2
355

MATE1
135

MATE2
96
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
773
 no
BSEP
403
 no
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
CYP3A4/5
335
 no
MATE1
308
 no
MATE2
263
 no
OAT1
603
 no
OATP1B1
803
 no
OCT1
543
 no
OCT2
648
 no
CYP2C8
965
 weak [Inhibition 85.6 uM]
OAT3
644
 yes [Inhibition 36 uM]
OATP1B3
715
 yes [Inhibition 36 uM]
P-gp
1650
 yes [Inhibition 36 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
561
 no
BSEP
52
 no
MATE1
135
 no
MATE2
96
 no
OAT1
326
 no
OAT3
339
 no
OATP1B1
406
 no
OATP1B3
350
 no
OCT1
327
 no
OCT2
355
 no
P-gp
1537
 no
UGT
192
 yes
CYP3A
191
 yes
yes (co-administration study)
Comment: Concomitant use of itraconazole (strong CYP3A inhibitor) increased eravacycline Cmax by 5% and AUC by 32%, and decreased eravacycline clearance by 32%
Page: 13.0
CYP3A4/5
85
 yes
yes (co-administration study)
Comment: Concomitant use of rifampin (strong CYP3A4/3A5 inducer) decreased eravacycline AUC by 35% and increased eravacycline clearance by 54%
Page: 13.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA008ZRJ
https://www.aablocks.com/goods/Goods/detail?id=AA008ZRJ
Achemtek
0102-028649
http://www.achemtek.com/1207283-85-9
BioSynth
J-690064
https://www.biosynth.com/en/products/all-products/products/J-690077.html
Chem Scene
CS-7564
http://www.chemscene.com/1207283-85-9.html
ChemFish Tokyo co.,ltd
54726192
http://www.chemfish.co.jp/index.php?id=4631&project=product
ChemShuttle
169624
http://www.chemshuttle.com/catalogsearch/result/?q=1207283-85-9&cat=
Chemspace
CSSB00102419706
https://chem-space.com/CSSB00102419706
Excenen
EX-A751
http://www.excenen.com/searchresultlist.php?id=1207283-85-9
Hairui
ERSA029
http://www.hairuichem.com/en/product/1207283-85-9.html
Lab Network
LN01297610
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01297610
MedChem Express
HY-16980
https://www.medchemexpress.com/Eravacycline.html
MuseChem
I006700
https://www.musechem.com/product/I006700.html
abcr GmbH
AB402282
http://www.abcr.com/shop/en/AB402282
eNovation Chemicals
D516656
https://www.enovationchem.com/ProductDetails.asp?ProductID=D516656
PubMed

PubMed

TitleDatePubMed
Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
2012 Jan 26
Patents

Patents

20100105671
2
20120302527
2

Sample Use Guides

In Vivo Use Guide
Administer XERAVA for injection 1 mg/kg by intravenous infusion over approximately 60 minutes every 12 hours for a total duration of 4 to 14 days. (2.1) • Severe Hepatic Impairment (Child Pugh C): 1 mg/kg XERAVA every 12 hours on Day 1, then 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days. (2.2) • Concomitant Use of a Strong Cytochrome P450 Isoenzymes (CYP)3A Inducer: 1.5 mg/kg XERAVA every 12 hours for a total duration of 4 to 14 days. (2.3) For injection: 50 mg of eravacycline (equivalent to 63.5 mg eravacy cline dihydrochloride) as a lyophilized powder in a single-dose vial for reconstitution and further dilution.
Route of Administration: Intravenous
In Vitro Use Guide
In vitro activity data from Tetraphase Pharmaceuticals studies on the following groups of combined bacterial species: Enterobacteriaceae, 5975 isolates, MIC90 0.5 mcg/mL, ECOV 1 ug/mL All Enterococcus spp., 1403 isolates, MIC90 0.06 ug/mL, ECOV 0.25 ug/mL All Viridans Group Streptococcus, 414 isolates, MIC90 0.06 ug/mL, ECOV 0.12 ug/mL Anaerobes, 1190 isolates, MIC90 1 ug/mL, ECOV 1 ug/mL
Substance Class Chemical
Created
by admin
on Sat Dec 16 03:00:06 GMT 2023
Edited
by admin
on Sat Dec 16 03:00:06 GMT 2023
Record UNII
07896928ZC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERAVACYCLINE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
1-PYRROLIDINEACETAMIDE, N-((5AR,6AS,7S,10AS)-9-(AMINOCARBONYL)-7-(DIMETHYLAMINO)-4-FLUORO-5,5A,6,6A,7,10,10A,12-OCTAHYDRO-1,8,10A,11-TETRAHYDROXY-10,12-DIOXO-2-NAPHTHACENYL)-
Systematic Name English
ERAVACYCLINE [USAN]
Common Name English
Eravacycline [WHO-DD]
Common Name English
TP-434
Code English
eravacycline [INN]
Common Name English
ERAVACYCLINE [MI]
Common Name English
4S,4AS,5AR,12AS)-4-(DIMETHYLAMINO)-7-FLUORO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-9-((PYRROLIDIN-1-YLACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
Systematic Name English
(4S,4AS,5AR,12AS)-4-(DIMETHYLAMINO)-7-FLUORO-3,10,12,12ATETRAHYDROXY-1,11-DIOXO-9-(2-(PYRROLIDIN-1-YL)ACETAMIDO)-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
Systematic Name English
Classification Tree Code System Code
WHO-ATC J01AA13
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
Code System Code Type Description
DRUG BANK
DB12329
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
ChEMBL
CHEMBL1951095
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
LACTMED
Eravacycline
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID401026285
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
RXCUI
2055906
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
CAS
1207283-85-9
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
MERCK INDEX
m12118
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
NCI_THESAURUS
C171907
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
WIKIPEDIA
Eravacycline
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
USAN
ZZ-69
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
INN
9702
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
FDA UNII
07896928ZC
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
SMS_ID
100000174218
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
DAILYMED
07896928ZC
Created by admin on Sat Dec 16 03:00:07 GMT 2023 , Edited by admin on Sat Dec 16 03:00:07 GMT 2023
PRIMARY
Related Record Type Details
Structure of ERAVACYCLINE DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
ENTEROCOCCUS FAECALIS
TARGET ORGANISM->INHIBITOR
MIC90
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 1 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
STREPTOCOCCUS ANGINOSUS
TARGET ORGANISM->INHIBITOR
Structure of ERAVACYCLINE
EXCRETED UNCHANGED
FECAL
ESCHERICHIA COLI
TARGET ORGANISM->INHIBITOR
MIC90
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
DIMETHYLANILINE MONOOXYGENASE (N-OXIDE-FORMING) 5
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.
BINDING
Structure of ERAVACYCLINE
EXCRETED UNCHANGED
URINE
Related Record Type Details
Structure of TP-498
METABOLITE INACTIVE -> PARENT
MAJOR
Structure of TP-034
METABOLITE INACTIVE -> PARENT
MAJOR
Structure of TP-6208
METABOLITE INACTIVE -> PARENT
MAJOR
Related Record Type Details
Structure of ERAVACYCLINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life ENZYMATIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966